Literature DB >> 19782095

Aldosterone as a renal growth factor.

Warren Thomas1, Ruth Dooley, Brian J Harvey.   

Abstract

Aldosterone regulates blood pressure through its effects on the cardiovascular system and kidney. Aldosterone can also contribute to the development of hypertension that leads to chronic pathologies such as nephropathy and renal fibrosis. Aldosterone directly modulates renal cell proliferation and differentiation as part of normal kidney development. The stimulation of rapidly activated protein kinase cascades is one facet of how aldosterone regulates renal cell growth. These cascades may also contribute to myofibroblastic transformation and cell proliferation observed in pathological conditions of the kidney. Polycystic kidney disease is a genetic disorder that is accelerated by hypertension. EGFR-dependent proliferation of the renal epithelium is a factor in cyst development and trans-activation of EGFR is a key feature in initiating aldosterone-induced signalling cascades. Delineating the components of aldosterone-induced signalling cascades may identify novel therapeutic targets for proliferative diseases of the kidney. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782095     DOI: 10.1016/j.steroids.2009.09.008

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  8 in total

1.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

Review 2.  Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.

Authors:  Andrew S Brem; Rujun Gong
Journal:  Clin Sci (Lond)       Date:  2015-05       Impact factor: 6.124

Review 3.  Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?

Authors:  Hermann Haller; Anna Bertram; Klaus Stahl; Jan Menne
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

4.  Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells.

Authors:  Jose L Morgado-Pascual; Sandra Rayego-Mateos; Jose M Valdivielso; Alberto Ortiz; Jesus Egido; Marta Ruiz-Ortega
Journal:  Biomed Res Int       Date:  2015-05-06       Impact factor: 3.411

5.  Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring.

Authors:  Ana Konvalinka; Ihor Batruch; Tomas Tokar; Apostolos Dimitromanolakis; Shelby Reid; Xuewen Song; York Pei; Andrei P Drabovich; Eleftherios P Diamandis; Igor Jurisica; James W Scholey
Journal:  Clin Proteomics       Date:  2016-08-05       Impact factor: 3.988

6.  Activation of mineralocorticoid receptor by ecdysone, an adaptogenic and anabolic ecdysteroid, promotes glomerular injury and proteinuria involving overactive GSK3β pathway signaling.

Authors:  Minglei Lu; Pei Wang; Yan Ge; Lance Dworkin; Andrew Brem; Zhangsuo Liu; Rujun Gong
Journal:  Sci Rep       Date:  2018-08-15       Impact factor: 4.379

Review 7.  Zebrafish as an animal model to study ion homeostasis.

Authors:  Pung-Pung Hwang; Ming-Yi Chou
Journal:  Pflugers Arch       Date:  2013-04-09       Impact factor: 3.657

8.  Hypokalemic Hypertension Leading to a Diagnosis of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Wasawat Vutthikraivit; Montira Assanatham; Chutintorn Sriphrapradang
Journal:  Electrolyte Blood Press       Date:  2016-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.